{{Rsnum
|rsid=10184275
|Gene=SCN2A
|Chromosome=2
|position=165271418
|Orientation=plus
|GMAF=0.1561
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=SCN2A
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 66.4 | 31.9 | 1.8
| HCB | 59.9 | 31.4 | 8.8
| JPT | 59.3 | 34.5 | 6.2
| YRI | 99.3 | 0.7 | 0.0
| ASW | 91.2 | 8.8 | 0.0
| CHB | 59.9 | 31.4 | 8.8
| CHD | 61.5 | 31.2 | 7.3
| GIH | 74.3 | 22.8 | 3.0
| LWK | 99.1 | 0.9 | 0.0
| MEX | 56.9 | 37.9 | 5.2
| MKK | 98.1 | 1.9 | 0.0
| TSI | 78.4 | 21.6 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs10184275
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19118814
|Annotation=This variant is significantly associated with late-onset Alzheimer disease (LOAD) in a GWAS study with 492 LOAD cases and 498 cognitive controls using Illumina's HumanHap550 beadchip.
|Drugs=
|Drug Classes=
|Diseases=Alzheimer Disease
|Curation Level=Curated
|PharmGKB Accession ID=PA162363815
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10184275
|overall_frequency_n=109
|overall_frequency_d=128
|overall_frequency=0.851562
|n_genomes=53
|n_genomes_annotated=0
|n_haplomes=94
|n_articles=1
|n_articles_annotated=1
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}